Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Second-Line Therapy for Advanced NSCLC.

The oncologist - 1 Jan 2013

Weiss Jared M, Stinchcombe Thomas E

Abstract excerpt

Most patients with lung cancer have non-small cell lung cancer (NSCLC) subtype and have advanced disease at the time of diagnosis. Improvements in both first-line and subsequent therapies are allowing longer survival and enhanced quality of life for these patients. The median overall survival observed in many second-line trials is approximately 9 months, and many patients receive further therapy after second-line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Docetaxel
Share to Erlotinib Hydrochloride
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutamates

Share to Guanine

Share to Oncogene Proteins, Fusion

Share to Pemetrexed

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 23918070
DOI: 10.1634/theoncologist.2013-0096
PMCID: PMC3755933

Genes

EGFR
ALK
EML4
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Second-Line Therapy for Advanced NSCLC.PMID 23918070Read ↗

Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation.Semantic proximity Read ↗

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary managementSemantic proximity Read ↗

Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.Semantic proximity Read ↗

Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options.Semantic proximity Read ↗

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.Semantic proximity Read ↗

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.Semantic proximity Read ↗

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?Semantic proximity Read ↗

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.Semantic proximity Read ↗

Personalized therapy for lung cancer: striking a moving target.Semantic proximity Read ↗

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.